Nasdaq Sends Delisting Notice to Estrella Immunopharma Over Sub-$1.00 Bid Price
ESLA is trading near its 52-week low of $0.678 (8.4% above the low) on light trading volume (0.2× avg).
Summary
Estrella Immunopharma received a Nasdaq delisting notice after its stock traded below $1.00 for 30 consecutive days. The company has until February 16, 2027 to regain compliance, potentially via a reverse stock split.
Key Events · Legal and Risk Events · ESLA
-
Nasdaq Delisting Notice Received
On August 17, 2026, Nasdaq notified Estrella Immunopharma that its common stock closed below $1.00 for 30 consecutive business days (July 6 – August 14, 2026), violating Listing Rule 5550(a)(2).
-
180-Day Compliance Period
The company has until February 16, 2027 to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
-
Reverse Stock Split Likely
To regain compliance, the company may implement a reverse stock split, which must be completed no later than ten business days before the compliance deadline.
-
Financial Distress Compounds Risk
The delisting notice follows the company's Q2 10-Q disclosing going concern doubt with only $0.1M cash against $9.3M current liabilities, heightening the risk of delisting.
Analysis · ESLA · Life Sciences
A formal notice from Nasdaq has put Estrella Immunopharma on the clock: its stock has traded below the $1.00 minimum bid requirement for 30 consecutive business days. The company now has 180 days, until February 16, 2027, to regain compliance, likely through a reverse stock split. This development compounds an already precarious situation—a going-concern warning and just $0.1M in cash disclosed in the recent 10-Q—making the delisting threat a critical risk to the company's survival.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESLA was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32M. The 52-week trading range was $0.68 to $3.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.